| Product Code | DAT08647 |
|---|---|
| Publication Date | November 2007 |
| Publisher | Datamonitor |
| Product Type | Report |
| Pages | 59 |
The company was founded based on a license to the DUROS technology for specific therapeutic areas. DURECT subsequently acquired and developed additional advanced technologies to address a range of specific drug delivery challenges and enable the development of a broad product pipeline. The company's acquisition of IntraEar and Southern BioSystems further broadened its product offerings.
DURECT is a specialty pharmaceutical company focused on the development of pharmaceutical products based on its drug delivery technology platforms: SABER Delivery System, ORADUR, TRANSDUR Delivery System, DURIN Biodegradable Implant, DUROS System and MICRODUR.
The company currently manufactures and sells finished products, ALZET and LACTEL. The company's lead proprietary candidate, ELADUR (TRANSDUR-Bupivacaine) is currently in Phase II clinical trials.
The company's total revenues increased at a CAGR of 32.1% during 2002-2006, from $7.2 million to $21.9 million. The company's biggest contributor to revenue growth during 2002-2006 was revenues from license, collaboration and others.
PDF:Delivered by email usually within 4 to 8 UK business hours.
PRINT/CD-ROM:Despatched within 1 to 2 working days.
© 2010 | Report Buyer is a trading name for Piribo Ltd. Registered in England and Wales No. 05051530 | VAT Reg No. GB 839 4556 85